(Q46900712)

26 December 2017

title

Determining the Value of Disease Management Programs (English)

1 reference

https://api.crossref.org/works/10.1016/S1549-3741(03)29059-6

15 March 2024

author name string

Dennis Scanlon

2

1 reference

26 December 2017

Jennifer Elston Lafata

3

1 reference

26 December 2017

Victor Villagra

4

1 reference

26 December 2017

Jeff Beich

5

1 reference

26 December 2017

Joe V. Selby

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14513673

15 March 2024

Patricia R. Salber

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14513673

15 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14513673

15 March 2024

publication date

1 September 2003

1 reference

26 December 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S1549374103290596?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1549-3741(03)29059-6

https://api.elsevier.com/content/article/PII:S1549374103290596?httpAccept=text/plain

15 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1549-3741(03)29059-6

Joint Commission journal on quality and safety

15 March 2024

published in

1 reference

26 December 2017

volume

29

1 reference

26 December 2017

issue

9

1 reference

26 December 2017

page(s)

491-499

1 reference

26 December 2017

Persons with chronic conditions. Their prevalence and costs

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Improving chronic illness care: translating evidence into action

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

A diabetes report card for the United States: quality of care in the 1990s

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Evidence-based disease management

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

From outcomes research to disease management: a guide for the perplexed

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Excess costs of medical care for patients with diabetes in a managed care population

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Photocoagulation for Diabetic Macular Edema

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Model of complications of NIDDM. I. Model construction and assumptions.

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

The effects of treatment on the direct costs of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Nurse case management to improve glycemic control in diabetic patients in a health maintenance organization. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Group visits improve metabolic control in type 2 diabetes: a 2-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Chronic care clinics for diabetes in primary care: a system-wide randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

An economic analysis of interventions for diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Estimated benefits of glycemic control in microvascular complications in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

The global diabetes model: user friendly version 3.0.

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Archimedes: a new model for simulating health care systems--the mathematical formulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

The Mt. Hood challenge: cross-testing two diabetes simulation models

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

The unreliability of individual physician "report cards" for assessing the costs and quality of care of a chronic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Comparing the national economic burden of five chronic conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Productivity and medical costs of diabetes in a large employer population.

1 reference

https://api.crossref.org/works/10.1016%2FS1549-3741%2803%2929059-6

7 January 2021

Disease management advisor

7

8

117

2002

1 reference

https://api.crossref.org/works/10.1016/S1549-3741(03)29059-6

Disease management advisor

15 March 2024

8

7

52

2001

1 reference

https://api.crossref.org/works/10.1016/S1549-3741(03)29059-6

Health care strategic management

15 March 2024

12

1

6

2000

1 reference

https://api.crossref.org/works/10.1016/S1549-3741(03)29059-6

Clinical and economic impact of implementing a comprehensive diabetes management program in managed care

15 March 2024

39

1 reference

https://api.crossref.org/works/10.1016/S1549-3741(03)29059-6

15 March 2024

Identifiers

1 reference

26 December 2017

release_3pqmnqv5bzbtrpxva4mzmj6owm

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/3pqmnqv5bzbtrpxva4mzmj6owm

24 November 2022

mapped directly with Wikidata item

1 reference

26 December 2017